Canaccord analyst Whitney Ijem lowered the firm’s price target on BioMarin to $89 from $91 and keeps a Hold rating on the shares. The firm noted investor focus remains on the bigger announcements/greater clarity that is expected at the company’s September investor day rahter than the day’s headline surrounding Roctavian struggles and the company’s trimmed pipeline expenses.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin price target lowered to $91 from $94 at Citi
- BioMarin price target raised to $110 from $100 at Wells Fargo
- BioMarin raises FY24 adjusted EPS view to $2.75-$2.95 from $2.60-$280
- BioMarin reports Q1 non-GAAP EPS 71c, consensus 34c
- BioMarin Reports Record Financial Results for the First Quarter 2024